New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
08:14 EDTEPZMEpizyme announces publication of preclinical data for EPZ-6438
Epizyme announced the publication of data from preclinical studies of the company's clinical candidate EPZ-6438, a potent and selective small-molecule inhibitor of EZH2, a histone methyltransferase. Oncogenic mutations in EZH2 occur in a subset of patients with non-Hodgkin lymphoma, implicating EZH2 as a therapeutic target in these patients. Detailed characterization of the correlation between EZH2 inhibition, methylation of the EZH2 target (H3K27), reversal of lymphomagenic gene expression and antiproliferative effects specific to EZH2 mutant-bearing NHL cell lines. Sustained tumor growth inhibition in animal models of EZH2 mutant-bearing NHL, including durable effects after drug dosing is discontinued.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
07:41 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information
June 22, 2015
13:20 EDTEPZMOn The Fly: Top stock stories at midday
Subscribe for More Information
June 21, 2015
15:09 EDTEPZMEpizyme to hold a conference call
Subscribe for More Information
12:37 EDTEPZMEpizyme reports phase 1 tazemetostat results, plans phase 2 trial in Q2
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use